Ancora Advisors’s CERo Therapeutics Warrants CEROW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4 | Hold |
2,500
| – | – | ﹤0.01% | 1975 |
|
|
2026
Q1 | $11 | Hold |
2,500
| – | – | ﹤0.01% | 2374 |
|
|
2025
Q4 | $22 | Hold |
2,500
| – | – | ﹤0.01% | 2410 |
|
|
2025
Q3 | $33 | Hold |
2,500
| – | – | ﹤0.01% | 1938 |
|
|
2025
Q2 | $59 | Hold |
2,500
| – | – | ﹤0.01% | 1929 |
|
|
2025
Q1 | $36 | Hold |
2,500
| – | – | ﹤0.01% | 1739 |
|
|
2024
Q4 | $21 | Hold |
2,500
| – | – | ﹤0.01% | 1798 |
|
|
2024
Q3 | $13 | Hold |
2,500
| – | – | ﹤0.01% | 1765 |
|
|
2024
Q2 | $50 | Hold |
2,500
| – | – | ﹤0.01% | 1803 |
|
|
2024
Q1 | $170 | Hold |
2,500
| – | – | ﹤0.01% | 1742 |
|
|
2023
Q4 | $69 | Hold |
2,500
| – | – | ﹤0.01% | 1713 |
|
|
2023
Q3 | $179 | Hold |
2,500
| – | – | ﹤0.01% | 1701 |
|
|
2023
Q2 | $163 | Hold |
2,500
| – | – | ﹤0.01% | 1717 |
|
|
2023
Q1 | $100 | Hold |
2,500
| – | – | ﹤0.01% | 1897 |
|
|
2022
Q4 | $0 | Hold |
2,500
| – | – | ﹤0.01% | 1979 |
|
|
2022
Q3 | $0 | Hold |
2,500
| – | – | ﹤0.01% | 2192 |
|
|
2022
Q2 | $0 | Hold |
2,500
| – | – | ﹤0.01% | 2352 |
|
|
2022
Q1 | $1K | Buy |
+2,500
| New | +$929 | ﹤0.01% | 2273 |
|
Ancora Advisors's CEROW Position: Q2 2026 in Review
Ancora Advisors held its CERo Therapeutics Warrants (CEROW) position steady in Q2 2026 at 2,500 shares worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #1975.
Ancora Advisors first reported a position in CEROW in Q1 2022 and has held it in 18 quarters since. The position peaked at $1K in Q1 2022. 1 fund tracked by Wall St. Rank holds CEROW as of Q2 2026.
- Ancora Advisors held 2,500 shares of CERo Therapeutics Warrants worth $4 as of Q2 2026.
- Ancora Advisors left its CERo Therapeutics Warrants share count unchanged in Q2 2026.
- CERo Therapeutics Warrants made up ﹤0.01% of Ancora Advisors's portfolio in Q2 2026, its #1975 holding.
- Ancora Advisors first reported a position in CERo Therapeutics Warrants in Q1 2022 and has held it in 18 quarters since.
- Ancora Advisors's CERo Therapeutics Warrants position peaked at $1K in Q1 2022.
- 1 fund tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q2 2026.
Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.